⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5804483 | 0.77 | — | — | |
| SCHEMBL6899852 | 0.72 | — | — | |
| SCHEMBL382648 | 0.71 | — | — | |
| SCHEMBL43134 | 0.71 | — | — | |
| SCHEMBL82518 | 0.71 | — | — | |
| SCHEMBL6228272 | 0.71 | — | — | |
| SCHEMBL27777048 | 0.71 | — | — | |
| Fluoride SCHEMBL11511430 | 0.68 | — | — | |
| SCHEMBL2220091 | 0.67 | — | — | |
| SCHEMBL11007560 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117384072-A | Synthesis method of difluoro alkyl sulfide | 上海筛杰生物医药有限公司 | 2024-01-12 | — | — | CN | disclosed |
| US-20220220095-A1 | N-((HETEROARYL)METHYL)-1-TOSYL-1H-PYRAZOLE-3-CARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | H LUNDBECK AS (DK) | 2022-07-14 | — | — | US | disclosed |
| US-20220204489-A1 | ARYLSULFONYLTHIOPHENECARBOXAMIDES AND ARYLSULFONYLFURANCARBOXAMIDES AS Kv3 POTASSIUM CHANNEL ACTIVATORS | H LUNDBECK AS (DK) | 2022-06-30 | — | — | US | disclosed |
| CN-113710318-A | Arylsulfonyl thiophenecarboxamides and arylsulfonyl furancarboxamides as Kv3 potassium channel activators | H.隆德贝克有限公司 | 2021-11-26 | — | — | CN | disclosed |
| CN-113692405-A | Derivatives of N- ((heteroaryl) methyl) -1-tosyl-1H-pyrazole-3-carboxamide as KV3 potassium channel activators for the treatment of neurological or psychiatric disorders | H.隆德贝克有限公司 | 2021-11-23 | — | — | CN | disclosed |
| EP-3873891-A1 | ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS KV3 POTASSIUM CHANNEL ACTIVATORS | H. Lundbeck A/S (DK) | 2021-09-08 | — | — | EP | disclosed |
| CN-113056461-A | Arylsulfonyl pyrrole carboxamide derivatives as Kv3 potassium channel activators | H.隆德贝克有限公司 | 2021-06-29 | — | — | CN | disclosed |
| CN-110204468-B | Asymmetric synthesis method of chiral alpha-thiocyano cyclic ketonic acid ester compound | 浙江工业大学 | 2021-02-02 | — | — | CN | disclosed |
| US-10870646-B2 | Oxazolidinones and pharmaceutical compositions thereof for treating bacterial infections, including infection of Mycobacterium tuberculosis | UNIVERSITY OF ST. THOMAS (US) | 2020-12-22 | — | — | US | disclosed |
| WO-2020216919-A1 | ARYLSULFONYLTHIOPHENECARBOXAMIDES AND ARYLSULFONYLFURANCARBOXAMIDES AS Kν3 POTASSIUM CHANNEL ACTIVATORS | H. LUNDBECK A/S (DK) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020216920-A1 | N-((HETEROARYL)METHYL)-1-TOSYL-1H-PYRAZOLE-3-CARBOXAMIDE DERIVATIVES AS KV3 POTASSIUM CHANNEL ACTIVATORS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | H. LUNDBECK A/S (DK) | 2020-10-29 | — | — | WO | disclosed |
| US-20200131156-A1 | ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS | H. LUNDBECK A/S (DK) | 2020-04-30 | — | — | US | disclosed |
| WO-2018157043-A1 | OXAZOUDINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR TREATING BACTERIAL INFECTIONS, INCLUDING INFECTION OF MYCOBACTERIUM TUBERCULOSIS | UNIVERSITY OF ST. THOMAS (US) | 2018-08-30 | — | — | WO | disclosed |
| US-7846960-B2 | FXR agonists | ELI LILLY AND COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| EP-2029547-B1 | FXR AGONISTS | LILLY CO ELI (US) | 2010-04-28 | — | — | EP | disclosed |
| US-20090270460-A1 | FXR AGONISTS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-10-29 | — | — | US | disclosed |
| EP-2029547-A1 | FXR AGONISTS | ELI LILLY AND COMPANY (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007140183-A1 | FXR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |